Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection
Publication
, Journal Article
Stout, JE
Published in: Expert Opinion on Drug Safety
2004
Duke Scholars
Published In
Expert Opinion on Drug Safety
DOI
ISSN
1474-0338
Publication Date
2004
Volume
3
Issue
3
Start / End Page
187 / 198
Publisher
Informa UK Limited
Related Subject Headings
- Pharmacology & Pharmacy
- 3214 Pharmacology and pharmaceutical sciences
- 3202 Clinical sciences
- 1115 Pharmacology and Pharmaceutical Sciences
- 1007 Nanotechnology
Citation
APA
Chicago
ICMJE
MLA
NLM
Stout, J. E. (2004). Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opinion on Drug Safety, 3(3), 187–198. https://doi.org/10.1517/eods.3.3.187.31073
Stout, Jason E. “Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.” Expert Opinion on Drug Safety 3, no. 3 (2004): 187–98. https://doi.org/10.1517/eods.3.3.187.31073.
Stout JE. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opinion on Drug Safety. 2004;3(3):187–98.
Stout, Jason E. “Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.” Expert Opinion on Drug Safety, vol. 3, no. 3, Informa UK Limited, 2004, pp. 187–98. Crossref, doi:10.1517/eods.3.3.187.31073.
Stout JE. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opinion on Drug Safety. Informa UK Limited; 2004;3(3):187–198.
Published In
Expert Opinion on Drug Safety
DOI
ISSN
1474-0338
Publication Date
2004
Volume
3
Issue
3
Start / End Page
187 / 198
Publisher
Informa UK Limited
Related Subject Headings
- Pharmacology & Pharmacy
- 3214 Pharmacology and pharmaceutical sciences
- 3202 Clinical sciences
- 1115 Pharmacology and Pharmaceutical Sciences
- 1007 Nanotechnology